Cetuximab co‑treatment with KRAS G12C inhibitors fulzerasib and sotorasib in human KRAS G12C non‑small cell lung cancer cells
Cetuximab enhanced the antitumor growth effect of fulzerasib in vitro in H358 cells and prolonged the survival of mice bearing subcutaneous H358 xenografts.
Resistance to KRAS G12C inhibitors is a major cause of poor prognosis in non‑small cell lung cancer (NSCLC). The study evaluates the combination of cetuximab, an EGFR‑monoclonal antibody, with KRAS G12C‑specific covalent inhibitors fulzerasib and sotorasib in KRAS G12C‑mutant NSCLC cell lines in vitro and in vivo. The combination enhances antitumor activity and suppresses MAPK re‑activation compared with single agents, supporting further clinical investigation.
KRAS G12C mutations represent a therapeutic target in NSCLC, and concurrent EGFR inhibition may overcome intrinsic resistance to KRAS inhibitors by blocking MAPK signaling rebound.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT